[144] Ascendis Pharma A/S American SEC Filing

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) filing a Form 144 notifies the market of a proposed sale of 3,000 American Depositary Shares with an aggregate market value of $578,385. The shares represent part of 55,635,376 shares outstanding and are scheduled for sale on 08/20/2025 through Goldman Sachs & Co. LLC. The filer reports acquisition of the 3,000 ADS on 08/20/2025 via warrant exercise and payment in cash. The filing states there were no sales by the filer in the prior three months and includes the standard Rule 144 representation about no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice for a small proposed sale following a warrant exercise; appears to be a compliance disclosure, not material company news.

The filing discloses a proposed sale of 3,000 ADS valued at $578,385 to be executed through Goldman Sachs on 08/20/2025. The securities were acquired the same day via warrant exercise and paid in cash, and no sales occurred in the prior three months. For investors, this is a transactional disclosure required under Rule 144 and does not itself provide information on company operations or financial performance. The size of the sale relative to outstanding shares (3,000 versus 55,635,376) suggests limited market impact absent larger, related insider activity.

Corporate Governance Expert

TL;DR: Filing reflects appropriate insider disclosure and the standard Rule 144 attestation; governance processes appear followed.

The notice identifies the broker, acquisition method (warrant exercise), payment method (cash), and affirms the filer is not aware of undisclosed material adverse information. These elements are consistent with compliance expectations for insider sales under Rule 144. The absence of reported sales in the prior three months and the explicit representation reduce procedural concerns, though the filing does not include identity details of the selling person or relationship to the issuer in the provided text.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	3000	578385	55635376	08/20/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	08/20/2025	Warrant Exercise	Issuer			3000	08/20/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)